Table 4.
Overall response (OR) rates and overall survival (OS) achieved in HIV negative and positive patients according to the treatment modalities used
| Treatment | n | OR | P | Median OS ± SE (mos) | P |
|---|---|---|---|---|---|
| WBRT only | |||||
| HIV− | 11 | 6 | NS | 10.3 ± 4.5 | |
| HIV+ | 2 | 0 | Not calculated | ||
| Chemotherapy only | |||||
| HIV− | 7 | 4 | NS | 21.3 ± 8.5 | NS |
| HIV+ | 16 | 9 | 4.0 ± 4.3 | ||
| WBRT + chemotherapy | |||||
| HIV− | 20 | 14 | NS | 23.8 ± 9.7 | 0.001 |
| HIV+ | 9 | 5 | 3.4 ± 1.5 | ||
| No treatment | |||||
| HIV− | 7 | 1.0 ± 10.9 | NS | ||
| HIV+ | 14 | 0.7 ± 0.3 |
HIV− N = 45; HIV+ N = 41
SE standard error, WBRT whole brain radiotherapy
Chemotherapy regimens used: DeAngelis protocol, fludarabine + cytarabine, high dose methotrexate with or without temozolomide, Azidothymidine in combination with hydroxyurea or high dose methotrexate or high dose IL-2 + ganciclovir